SCHEMBL16256552

SCHEMBL16256552

Cc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@H]2OC(C)(C)O[C@H]21

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 2/20 0.78
PI4K2B Q8TCG2 2/20 0.78
PI4K2A Q9BTU6 2/20 0.78
PI4KB Q9UBF8 2/20 0.78
ALDH1A1 P00352 1/20 0.57
LMNA P02545 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
RXFP1 Q9HBX9 1/20 0.54
P2RX1 P51575 1/20 0.52
P2RX3 P56373 1/20 0.52
P2RX4 Q99571 1/20 0.52
GAA P10253 1/20 0.51
OR51E2 Q9H255 1/20 0.50
AMD1 P17707 2/20 0.49
ADORA3 P0DMS8 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
DPP4 P27487 1/20 0.48
MEN1 O00255 1/20 0.48
SLC28A1 O00337 1/20 0.48
MAP3K7 O43318 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2291671 0.90 PI4KA (0.80) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL20133912 0.89 PI4KA (0.65) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL30586379 0.89 PI4KA (0.78) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL91054 0.88 PI4KA (0.77) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL20483753 0.88 PI4KA (1.00) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL24146588 0.88 PI4KA (1.00) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL21882960 0.88 PI4KA (0.77) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL22393059 0.88 PI4KA (1.00) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL9970446 0.88 PI4KA (1.00) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL18125984 0.88 PI4KA (1.00) PI4KAPI4K2BPI4K2API4KBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322715-A1 BROAD SPECTRUM ANTI-CANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-10-12 US disclosed
US-9289383-B2 Method of reducing intraocular pressure in humans INOTEK PHARMACEUTICALS CORPORATION (US) 2016-03-22 US disclosed
US-20150080330-A1 METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS INOTEK PHARMACEUTICALS CORPORATION 2015-03-19 US disclosed
US-8895530-B2 Method of reducing intraocular pressure in humans INOTEK PHARMACEUTICALS CORPORATION (US) 2014-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150080330-A1 METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS PDE3A, PDE2A, PDE6C PI4KA 2449/4885PI4K2B 2948/4885PI4K2A 2186/4885
US-20230322715-A1 BROAD SPECTRUM ANTI-CANCER COMPOUNDS YTHDF1, YTHDF3, YTHDF2 PI4KA 1123/4885PI4K2B 980/4885PI4K2A 813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.